Aurevia

Samuel Lagercrantz: ”Will the Swedish life science strategy be updated with precision?”

What will the Swedish government focus on in the life science strategy that is being updated? And what should be prioritized in the strategy? Life Science Swede...

Mercodia AB

Extremely high sample throughput rates

Precision and reliability in automated liquid handling

Life Science Sweden heads to the Oresund region! ‒ Hello there Michael Linnell

Life Science Sweden’s The Future of Swedish Danish Life Science and New Updates in Drug Formulation & Bioavailability meetings are coming up soon. We asked Michael Linnell, project...

No longer afraid of the dentist.

Teaching robot with piezo technology

The dock that “thinks” for itself

stations. In the process, cross-contamination can occur and dust can be released. The AZO CleanDock prevents this problem. Its latest generation can do even more: it “thinks” for itself. Directly attached to the dock, the integrated controller CEC of the modular...

Major investment in women’s health – for a more equal healthcare system

”The regional differences need to decrease and the long-term supply of midwives and other professions needs to be secured,” write Acko Ankarberg Johansson and D...

ZEISS Metrology Expert Tips

New video series provides valuable expert knowledge.

Astra Zeneca’s Sweden CEO: “We have great faith in our portfolio”

It all started with a summer job as an operator at Astra’s chemical factory in Snäckviken, just outside Södertälje. More than three decades and countless differ...

Improve Productivity and Accessibility with Award-winning Human-Centered Design

Enhance your workflow with integrated intelligence.

Galderma

Elypta awarded one million USD from the Star Trek creator’s foundation

Swedish company Elypta, which develops methods for early cancer detection, has been awarded one million USD from an unexpected source: a foundation set up in me...

Quality solutions for medical device R&D applications

From R&D to the quality assurance of series production in medical device manufacturing.

AZ gets approval for drug targeting rare disease – it may reduce cortisone dependence

AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.

New report: Fewer PhDs in life sciences

A new report from Vinnova suggests that competency returns in the life science sector are declining.

ZEISS Insights: Measurement of bone plates and screws

Get free access to technical paper.

Editorial: ”AI that both impresses and frightens”

”In the past, I've rarely been particularly impressed by something that was produced by AI. But this is something completely different”, Samuel Lagercrantz writ...

Business Sweden: “Companies have a lot to offer in data-driven precision medicine”

Data-driven precision medicine can potentially solve major healthcare problems, states Business Sweden in a new report on the subject.

Looking for greater Nordic cooperation – “We have Norway and Finland in our sights”

How can Medicon Valley Alliance bring the big pharmaceutical companies back to the organisation? Life Science Sweden discussed this topic and others with the cl...

Novartis storsatsar på RNA-terapier – köper miljardbolag

Novartis förvärvar amerikanska Avidity Biosciences för 12 miljarder dollar, motsvarande 113 miljarder kronor. Köpet stärker bolagets position inom sällsynta mus...

The key to successful collaboration between industry and academia

Why is collaboration between industry and academia necessary in the life sciences sector? What obstacles exist, and what is the key to successful collaboration?

Astra Zeneca’s asthma drug nears approval for sinus inflammation

Astra Zeneca’s drug Tezspire receives positive opinion from the European Medicines Agency (EMA) for the treatment of chronic rhinosinusitis with nasal polyps.

Marie Gårdmark: ”The situation is not satisfactory”

”The legislative tool-box is limited, but carrots in the form of longer exclusivity has already proven successful, this has for example increased registration of new products in rare diseases. But will it also work to increase access for all EU patients...